Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

Background/Aims In the GLOBE trial, telbivudine treatment was identified as a significant, independent predictor of better outcomes at 2 years. We analyzed all telbivudine recipients in this trial to determine the predictors of optimal outcomes. Methods The intent-to-treat population comprised 458 H...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2009-07, Vol.51 (1), p.11-20
Hauptverfasser:	Zeuzem, Stefan, Gane, Edward, Liaw, Yun-Fan, Lim, Seng G, DiBisceglie, Adrian, Buti, Maria, Chutaputti, Anuchit, Rasenack, Jens, Hou, Jinlin, O’Brien, Christopher, Nguyen, Tuan T, Jia, Jidong, Poynard, Thierry, Belanger, Bruce, Bao, Weibin, Naoumov, Nikolai V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Alanine Transaminase - blood Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - therapeutic use Biological and medical sciences Chronic hepatitis B DNA, Viral - blood Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen GLOBE trial Hepatitis B e Antigens - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Human viral diseases Humans Infectious diseases Lamivudine Medical sciences Middle Aged Nucleosides - therapeutic use Pharmacology. Drug treatments Predictors Pyrimidinones - therapeutic use Telbivudine Thymidine - analogs & derivatives Treatment Outcome Viral diseases Viral hepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!